Average common and common equivalent shares - diluted (in thousands)
37,326
37,231
37,005
36,900
37,006
Balance Sheet Data as of June 30:
201__6
201__5
201__4
201__3
201__2
Cash, cash equivalents and short-term available-for-sale investments
95,835
$
110,921
$
363,354
$
332,937
$
268,986
Working capital
199,744
208,515
443,022
377,432
310,757
Total assets
1,129,581
1,063,360
862,491
778,098
719,324
Total shareholders’ equity
879,280
846,935
795,265
737,541
674,442
Cash Flow Data:
201__6
201__5
201__4
201__3
201__2
Net cash provided by operating activities
$
143,870
$
139,359
$
136,762
$
123,562
$
126,746
Capital expenditures
16,898
19,904
13,821
22,454
6,017
Cash dividends declared per share
1.28
1.27
1.23
1.18
1.11
Employee Data as of June 30:
201__6
201__5
201__4
201__3
201__2
Employees
1,560
1,356
967
789
783
(1)
The Company acquired Cliniqa on July 8, 2015, and Zephyrus on March 21, 2016.
(2)
The Company acquired Novus Biologicals on July 2, 2014, ProteinSimple on July 31, 2014, and CyVek, on November 3, 2014.
(3)
The Company acquired Bionostics on July 22, 2013 and PrimeGene on April 30, 2014.
(4)
Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2016 - $37.6 million; 2015 - $37.6 million; 2014 - $20.0 million; 2013 - $10.2 million; 2012 - $12.7 million.
filings.tools